Primary Recipient

UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER, THE

Amount

$151,419.00

Award Date

9/01/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

Signaling transduction pathways and networks have recently proven to be attractive targets for cancer therapy. Gleevac, herceptin (TM), C225, Irressa, and CCI779 have all induced remarkable, non-toxic responses in a subset of patients where abnormalities